Evidence map›Paper›PMID 41230800›Full record

ArticleFEBS letters2025

The zinc finger domains of PARP-1 are selectively and potently inhibited by the Au(I)-based drugs sodium aurothiomalate and aurothioglucose.

Uliana Bashtanova, Melinda Jane Duer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Uliana BashtanovaYusuf Hamied Department of Chemistry, University of Cambridge, UK.ORCID https://orcid.org/0009-0002-9250-7804
Melinda Jane DuerYusuf Hamied Department of Chemistry, University of Cambridge, UK.

Funding

Cycle Pharmaceuticals Ltd
6 · The paper itself

Abstract

Poly(ADP-ribose) polymerase-1 (PARP-1) is a multidomain enzyme essential for the DNA damage response; its inhibition can lead to cancer cell death. Recruitment of PARP-1 to sites of genomic damage is mediated by its zinc finger domains. In this study, we investigated the inhibition of PARP-1's DNA-dependent activation by three Au(I)-based drugs, presumable zinc-ejectors. We found that aurothioglucose and sodium aurothiomalate selectively inhibited PARP-1's DNA-dependent activity, with IC

Indexed as

Poly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsZinc FingersAntineoplastic AgentsCell Line, TumorDNA ReplicationHumansAntineoplastic AgentsPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsauranofinaurothioglucoseaurothiomalatePoly(ADP‐ribose) polymerasesynthetic lethalityzinc finger

Identifiers

PMID41230800
PMCPMC12720219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.